1. Han, Bingfeng, et al. "Cancer incidence and mortality in China, 2022." Journal of the National Cancer Center (2024).
2. Lynge E, Vejborg I, Lillholm M, Nielsen M, Napolitano G, von Euler-Chelpin M. Breast density and risk of breast cancer. Int J Cancer. 2023 Mar 15;152(6):1150-1158. doi: 10.1002/ijc.34316. Epub 2022 Oct 27. PMID: 36214783 ; PMCID: PMC10091988.
3. 中国抗癌协会乳腺癌专业委员会,中华医学会肿瘤学分会乳腺肿瘤学组.中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 2023. DOl:10.19401 j.cnki. 1007-3639.2023.12.004.
4. 中国家族遗传性肿瘤临床诊疗专家共识 (2021年版)(1)-家族遗传性乳腺癌[J].中国肿瘤临床,2021,48(23):1189-1195.
5. 袁芃,徐兵河.中国晚期三阴性乳腺癌临床诊疗指南(2024版)[J]. Chinese Journal of Oncology, 2024, 46(6).DOl:10.3760/ cma..cn112152-20240118-00034.
6. He M, Jiang YZ, Gong Y, Fan L, Liu XY, Liu Y, Tang LC, Mo M, Hou YF, Di GH, Liu GY, Yu KD, Wu J, Yan X, Zeng XH, Fu DY, Song CG, Zhuang ZG, Wu KJ, Wang J, Wang ZH, Shao ZM. Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-IncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial. BMJ. 2024 Oct 23;387:e079603. doi: 10.1136/ bmj-2024-079603. PMID: 39442958; PMCID: PMC11497771.
7. Chen L, Li H, Zhang H, Yang H, Qian J, Li Z, Ren Y, Wang S, Fu P, Yang H, Liu Y, Sun J, Nie J, Lei R, Yao Y, Zhang A, Wang S, Ma X, Ouyang Z, Yang H, Wu SY, Cao SW, Wang K, Jiang A, Ouyang Q, Pang D, Wei L, Zha X, Shen Y, Qu X, Wu F, Zhu X, Wang Z, Fan L, Shao ZM. Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial. JAMA. 2025 Feb 25;333(8):673-681. doi: 10.1001 /jama.2024.23560. PMID:39671272.
8. Cai YW, Liu CC, Zhang YW, Liu YM, Chen L, Xiong X, Shao ZM, Yu KD. MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer. J Clin Invest. 2024 Nov 12;135(2):e183656. doi: 10.1172/JCI183656. PMID: 39531335; PMCID: PMC11735090.
深圳卫健委微信公众号
